Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Effects of Exercise Snacks on Endothelial Function and Body Composition in Overweight Individuals

22 de abril de 2026 actualizado por: Weifang Medical University
This randomized controlled trial investigates the effects of two types of stair-climbing exercise snacks versus moderate-intensity continuous training on vascular health, body composition, and blood lipids in overweight or obese adults. Participants will be assigned to one of four groups for 6-8 weeks. The control group receives no exercise intervention. Primary outcomes include endothelial function (ultrasound), body composition (InBody), and lipid profile (blood test).

Descripción general del estudio

Descripción detallada

This is a parallel group randomized controlled trial, with the study subjects being overweight or obese adults (with a body mass index of ≥ 24 kg/m²). Participants will be recruited from universities and randomly assigned to one of the following four groups:

Short-term stair climbing exercise group Participants climbed the stairs 4 to 5 times a day, each time ascending 5 floors (approximately 1 minute each time). There was at least a 1-hour interval between each exercise session, and the exercises were carried out during daily activities. They exercised 3 to 5 times a week for 6 to 8 weeks.

Long-term stair climbing nutrition supplementation group The participants also conducted 4 to 5 stair climbing training sessions every day. Each training session consisted of 3 sets of climbing 5 floors (the total climbing height for each training session was 15 floors), with a rest period of no more than 1 minute between each set. The interval between two training sessions was no less than 1 hour. They exercised 3 to 5 times a week for 6 to 8 weeks.

Moderate-intensity continuous training group (MICT) Participants engaged in 30-minute moderate-intensity running (including warm-up and cool-down activities) each time, 3 to 5 times a week, for 6 to 8 weeks.

Control group Participants maintained their daily activities and did not receive any exercise intervention measures.

Result measurement indicators:

Vascular health: Assessing endothelial function through ultrasound measurement of flow-mediated vascular dilation (FMD).

Body composition: Measured using the InBody body bioelectrical impedance analyzer (including muscle mass, fat mass and body fat percentage).

Blood lipid test: Collect fasting blood samples and measure low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and total cholesterol (TC).

Measurement time points: Measurements were conducted at the baseline (at the beginning of the study), 3-4 weeks (during the intervention period), and 8 weeks (after the intervention ended).

This research protocol has been approved by the Institutional Review Board of Shandong Second Medical University. All participants are required to sign a written informed consent form.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Age: 18-35 years old (male, female);
  2. Clear consciousness, stable vital signs;
  3. Able to understand and follow simple instructions;
  4. No regular exercise for at least 3 months;
  5. BMI ≥ 24 kg/m2.

Exclusion Criteria:

  1. There are other serious diseases, such as tumors;
  2. There are other neurological diseases;
  3. There are serious diseases that simultaneously affect the heart, liver, kidneys, endocrine system or hematopoietic system;
  4. There is a history of alcohol or drug abuse;
  5. Participated in other clinical trials that might affect the results of this study;
  6. There are other neurological or musculoskeletal diseases, with pain worsening with exercise;
  7. It is forbidden to engage in physical training.
  8. Within the past 3 months, there have been acute cardiovascular events such as acute myocardial infarction,unstable angina pectoris, severe arrhythmia, acute heart failure, etc.;
  9. Uncontrolled hypertension;
  10. Severe pulmonary diseases, such as uncontrolled asthma, acute exacerbation of chronic obstructive pulmonary disease, interstitial lung disease with significant exercise limitation;
  11. Severe joint and bone diseases, acute soft tissue injuries, fractures that have not healed, etc., making it impossible to complete the prescribed exercise load;
  12. Presence of bleeding tendencies, coagulation dysfunction, or within the past 1 month, there has been major bleeding or a history of surgery;
  13. The investigator judges that there are any other situations that may affect the safety of the subjects or the results of the trial.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Short-term stair climbing exercise snack group
Participants perform short climbs of the stairs 4 to 5 times a day. Each climb involves going up 5 floors (approximately 1 minute), and there is a minimum interval of at least 1 hour between each climb.
Adopt a fragmented approach, climbing stairs 4-5 times a day, each time climbing 5 floors (approximately 1 minute per session), with at least 1 hour of interval between each session, and spread throughout the daily activity periods. Exercise 3-5 days per week for a total of 6-8 weeks.
Experimental: Long-duration stair climbing exercise snack group
Participants climbed the ladder 4 to 5 times a day. Each climb consisted of 2 to 3 sets (each set involved climbing 5 floors, with a rest period of no more than 1 minute between sets), and the total number of floors climbed in a single session was 10 or 15.
On the basis of climbing stairs 4 to 5 times a day, increase the single exercise volume: complete 2 or 3 sets of climbing 5 floors of stairs each time (that is, the total number of floors climbed each time is 10 or 15), with no more than 1 minute of rest between sets. The intervals between each exercise should be at least 1 hour. Exercise 3 to 5 days a week, for a total of 6 to 8 weeks of intervention.
Experimental: Moderate-intensity continuous exercise
The participants engaged in moderate-intensity running training for 3 to 5 days per week, with each session lasting for 30 minutes.
Exercise 3 to 5 days per week for a total of 6 to 8 weeks. Perform 30 minutes of moderate-intensity running training every day.
Sin intervención: control group
The participants did not undergo any form of exercise intervention and maintained their usual activity patterns.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Flow-mediated dilation (FMD, relative percentage)
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Flow-mediated dilation expressed as a percentage of the baseline brachial artery diameter.Unit of Measure: %
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat mass
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat mass measured by bioelectrical impedance analysis (InBody device). Unit of Measure: kg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Time to peak dilation
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Time required to reach maximal dilation after cuff deflation.Unit of Measure: seconds
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Basal brachial artery diameter
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Baseline diameter of the brachial artery before cuff inflation.Unit of Measure: mm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Peak brachial artery diameter
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Maximal diameter of the brachial artery after reactive hyperemia.Unit of Measure: mm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Absolute flow-mediated dilation (FMDabs)
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Absolute change in diameter, calculated as peak diameter minus basal diameter.Unit of Measure: mm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Standardized FMD
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Flow-mediated dilation adjusted for relevant covariates (e.g., shear stress, baseline diameter) according to standard protocols.Unit of Measure: %
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body weight
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body weight measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat percentage
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body fat percentage measured by bioelectrical impedance analysis (InBody device).Unit of Measure: %
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body mass index (BMI)
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Body mass index calculated from weight and height measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg/m²
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Basal metabolic rate (BMR)
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Basal metabolic rate estimated by bioelectrical impedance analysis (InBody device).Unit of Measure: kcal
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Waist circumference
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Waist circumference measured by bioelectrical impedance analysis (InBody device).Unit of Measure: cm
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Visceral fat area
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Visceral fat area measured by bioelectrical impedance analysis (InBody device). Unit of Measure: cm²
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Skeletal muscle mass
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Skeletal muscle mass measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Systolic blood pressure (SBP)
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Systolic blood pressure measured using an electronic sphygmomanometer.Unit of Measure: mmHg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Serum high-density lipoprotein (HDL) cholesterol concentration
Periodo de tiempo: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum HDL cholesterol concentration measured from blood samples. Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).
Diastolic blood pressure (DBP)
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Diastolic blood pressure measured using an electronic sphygmomanometer. Unit of Measure: mmHg
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Heart rate
Periodo de tiempo: Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Heart rate measured using an electronic sphygmomanometer.Unit of Measure: bpm (beats per minute)
Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).
Serum low-density lipoprotein (LDL) cholesterol concentration
Periodo de tiempo: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum LDL cholesterol concentration measured from blood samples. Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).
Serum total cholesterol concentration
Periodo de tiempo: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum total cholesterol concentration measured from blood samples. Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).
HDL/LDL cholesterol ratio
Periodo de tiempo: Measured at baseline and post-intervention (after 6-8 weeks).
Ratio of serum HDL cholesterol to LDL cholesterol calculated from fasting blood samples.Unit of Measure: ratio (dimensionless)
Measured at baseline and post-intervention (after 6-8 weeks).
Serum triglyceride concentration
Periodo de tiempo: Measured at baseline and post-intervention (after 6-8 weeks).
Fasting serum triglyceride concentration measured from blood samples.Unit of Measure: mmol/L
Measured at baseline and post-intervention (after 6-8 weeks).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: YANXIA WANG, PhD, Weifang Medical University(Renamed Shandong Second Medical University)

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

16 de abril de 2026

Finalización primaria (Estimado)

16 de junio de 2026

Finalización del estudio (Estimado)

20 de julio de 2026

Fechas de registro del estudio

Enviado por primera vez

13 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

22 de abril de 2026

Publicado por primera vez (Actual)

30 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de abril de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de abril de 2026

Última verificación

1 de abril de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir